Top news of the day from across the health care landscape.
Diabetes
Latest News
Advertisement
CME Content
Advertisement
Top news of the day from across the health care landscape.
Immunotherapy may reverse type 1 diabetes.
Ertugliflozin (Steglatro) is also approved as part of 2 fixed-dose combinations.
Abbott has released its newest system for type 1 and 2 diabetes.
Now that Eli Lilly is looking to create a closed-loop system for diabetes management, does that mean this product will soon be available?
The cornerstone of working with patients is sharing decision-making and presenting information in a way that helps patients understand the risks and benefits of various choices.
HMG-CoA reductase inhibitors are a class of lipid-lowering medications. Here is a look at guidelines and studies for health care professionals.
Top articles of the week from The American Journal of Pharmacy Benefits.
Liver cancer is the most common cancer caused by diabetes and obesity.
Ademlog (insulin lispro injection) approved to control blood glucose levels among patients with diabetes.
Updated diabetes treatment guidelines address the use of the medications with potential cardiovascular benefit.
The American Diabetes Association (ADA) has released their annual Standards of Medical Care in Diabetes for 2018, highlighting several updated recommendations for diabetes care and management.
Top articles of the week from The American Journal of Pharmacy Benefits.
PD-L1-based immunotherapy observed to elicit long-lasting diabetes reversal in mice.
Diabetics using continuous glucose monitors were more aware of their blood sugar levels.
Top news of the day from across the healthcare landscape.
Top news of the day from across the health care landscape.
Patients with diabetes are significantly more likely to develop cardiovascular disease than nondiabetic patients.
The FDA issued approval to semaglutide injection (Ozempic) for type 2 diabetes.
The FDA has approved Novo Nordisk’s semaglutide injection (Ozempic), a glucagon-like peptide 1 (GLP-1) receptor agonist, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Between 10% and 20% of students in kindergarten through high school have chronic illness.
Nearly 700 million individuals around the world will develop diabetes by 2045, many of whom are undiagnosed.
Women with type 2 diabetes were 43% more likely to develop estrogen receptor negative breast cancer than patients without diabetes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Examining the Safety Profiles of SG and Pembrolizumab in ASCENT-04
2
The Unit-Based Pharmacist: Roles, Responsibilities, and Real Impact
3
RSV Vaccination as a Public Health Priority: Protecting Communities Through Pharmacy Access
4
Navigating the New Standard of Care: Patient Needs and the Pharmacist’s Critical Role in Perioperative MIBC Treatment
5
